Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $5.4 million.

  • Immunome's Gains from Investment Securities rose 414.34% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 414.34%. This contributed to the annual value of $6.6 million for FY2024, which is 1707.29% down from last year.
  • Immunome's Gains from Investment Securities amounted to $5.4 million in Q3 2025, which was up 414.34% from $902684.0 recorded in Q2 2025.
  • Immunome's 5-year Gains from Investment Securities high stood at $8.5 million for Q2 2024, and its period low was $348748.0 during Q1 2025.
  • Over the past 3 years, Immunome's median Gains from Investment Securities value was $4.1 million (recorded in 2023), while the average stood at $4.3 million.
  • As far as peak fluctuations go, Immunome's Gains from Investment Securities skyrocketed by 18103.27% in 2024, and later crashed by 9591.23% in 2025.
  • Immunome's Gains from Investment Securities (Quarter) stood at $5.8 million in 2023, then tumbled by 62.07% to $2.2 million in 2024, then surged by 144.85% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $902684.0 for Q2 2025, and $348748.0 during Q1 2025.